Proceedings from a CME symposium held at the 2019 ASCO Annual
Meeting. Featuring perspectives from Prof Jonathan A Ledermann and
Drs Joyce F Liu and David M O’Malley.
Introduction
Program overview: Dr Love (00:00)
Genetic Drivers of Ovarian Cancer Development and
Current Testing Algorithms; PARP Inhibitors in the Management of
Newly Diagnosed Disease (1:19)
Case (Dr Liu): A woman in her early 60s who presented with
gangrene of the fingers as a result of paraneoplastic syndrome and
was found to have high-grade serous ovarian cancer (1:30)
Case (Prof Ledermann): A woman in her early 70s with advanced
ovarian cancer and a germline BRCA1 mutation who is a Jehovah’s
Witness did not undergo debulking survey but enrolled on the SOLO-1
trial of maintenance olaparib (16:00)
Case (Dr O’Malley): A woman in her 60s with Stage IIIC
high-grade serous ovarian cancer with a somatic BRCA2 mutation who
underwent optimal debulking surgery and received IP chemotherapy
and maintenance olaparib (31:53)
Role of PARP Inhibition in the Management of Relapsed
Ovarian Cancer (35:09)
Case (Prof Ledermann): A nurse in her late 50s with BRCA
wild-type, platinum-sensitive recurrent ovarian cancer who received
niraparib maintenance therapy (43:03)
Case (Dr Liu): A woman in her early 60s with multiply relapsed
ovarian cancer and a germline BRCA2 mutation who received rucaparib
monotherapy (49:46)
Investigational Applications of Approved PARP
Inhibitors; Other PARP Inhibitors in Clinical Development
(57:09)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.